Brief: Spero Therapeutics Q4 EPS USD 0.97
13/03/2024 20:01
Mar 13 (Reuters) - Spero Therapeutics Q4 net income USD 51.192 million. * Q4 operating expenses USD 22.991 million * Q4 income from operation USD 50.533 million
Recent news on Spero Therapeutics
See all newsBrief: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Spero Therapeutics - May Offer Up To $300 Million In Securities - SEC Filing
Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)